ArticleACS central science2025
A Comparative Study of
Article in ACS central science, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Site-Selective B─H Activation via HAT Toward Xanthyl-closo-Carboranes as Bench-Stable Precursors of Organosulfur Boron Clusters.Angewandte Chemie (International ed. in English) · 2026Article
- Boron Neutron Capture Therapy at a Crossroads: Translational Gap and Emerging Delivery Agents.Chemistry (Weinheim an der Bergstrasse, Germany) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study investigates combined gadolinium and boron neutron capture therapy (GdBNCT) with carbonic anhydrase IX (CA IX) inhibition for mesothelioma treatment using a multifunctional platform (Gd-B-CA-SF). This platform incorporates a carborane cage for BNCT, a Gd complex for GdNCT/MRI, and a sulfamido group for CA IX inhibition. In vitro studies confirmed CA IX inhibition and selective binding of the compound to AB22 mesothelioma cells, with a 10-fold higher boron uptake compared to that in healthy Met-5a mesothelium. The combination of B and Gd in one molecule allows the exploration of potential additional effects coming from the nuclides
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.